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Abstract 
Aims/hypothesis In the double-blind placebo-controlled Fenofibrate Intervention and Event 
Lowering in Diabetes trial (n=9795), fenofibrate reduced major cardiovascular events in type 
2 diabetes. Sex-related differences in fenofibrate response could be clinically relevant and 
were pre-specified analyses. 
Methods Women (n=3657) and men (n= 6138) with type 2 diabetes not using statins were 
assigned fenofibrate (200 mg/day) or placebo for 5 years. Effects on lipoproteins and total 
cardiovascular events were evaluated by sex. 
Results Baseline total, LDL-, HDL- and non-HDL cholesterol and apolipoproteins A-I and B 
differed between sexes, and these and triacylglycerol levels improved with fenofibrate in both 
sexes (all p<0.001). Fenofibrate reduced total, LDL- and non-HDL cholesterol and 
apolipoprotein B more in women (all p<0.001), independent of menopausal status and statin 
uptake. Adjusted for covariates, fenofibrate reduced total cardiovascular outcomes 
(cardiovascular death, fatal and non-fatal stroke and carotid and coronary revascularisation) 
by 30% in women (95% CI 8%, 46%; p=0.008) and 13% in men (95% CI 5%, 61%; p=0.07) 
with no treatment-by-sex interaction (p>0.1). In patients with high triacylglycerol levels and 
low HDL-cholesterol, fenofibrate reduced total cardiovascular outcomes by 24% (95% CI 
2%, 42%) in women and 30% (7%, 54%) in men, with no treatment-by-sex interaction 
(p>0.1). 
Conclusions/interpretation Fenofibrate improved the lipoprotein profile more in women than 
men. Cardiovascular event reductions with fenofibrate among women were consistently 
similar to men, including among those with low HDL-cholesterol and high triacylglycerol 
levels. These data provide reassurance about fenofibrate efficacy in women and men. Both 
sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection. 
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Introduction 
Cardiovascular disease (CVD) is a major cause of death among women [1]. Women are more 
likely than men to die as a result of a first myocardial infarction (MI) or to have a second 
cardiovascular event [2]. In general, women have a more favourable lipid profile than men, but 
the differences diminish once women become postmenopausal [3]. Before the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study [4] some [5,6] but not all [7] fibrate 
trials had shown that long-term fibrate treatment reduced CVD events, although few women were 
randomised into fibrate trials [5,6,7]. More recently the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) Lipid study, which evaluated fenofibrate added to background simvastatin 
therapy, reported a 9.1% rate of CVD events for 851 women receiving fenofibrate and a non-
significantly lower rate of 6.6% in 843 women on placebo, although there was a significant 
interaction for treatment by sex, in favour of men (p=0.01) [8]. This raised questions about the 
role of fenofibrate as a therapy for women with diabetes and led to a safety alert being issued by 
the US Food and Drug Administration [9,10]. 
The FIELD study (n=9795, including 3657 women) is the largest study of fibrate use in 
women with diabetes (International Standard Randomised Controlled Trial [ISRCTN] registration 
no. 64783481). In FIELD, fenofibrate did not significantly reduce the primary endpoint of CHD 
events (non-fatal MI and CHD death; HR 0.89; 95% CI 0.75, 1.05, p=0.16) [4]. After adjustment 
for fenofibrate adherence and imbalanced uptake of statins and other cardiovascular drugs, this 
effect increased but remained non-significant (HR 0.84; 95% CI 0.69, 1.01, p=0.06) [11]. There 
was no significant interaction between fenofibrate treatment and sex on total CVD events (non-
fatal MI, stroke, all CVD death, and coronary and carotid revascularisation), the pre-specified 
endpoint for all subgroup analyses [4]. The FIELD study provides a unique opportunity to 
explore the effects of fenofibrate treatment by sex in more detail. This more detailed analysis 
addresses the potentially adverse findings for women in ACCORD Lipid. 
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Methods 
Study design and patients The study design, patient characteristics and outcome analysis of the 
FIELD trial have been reported [4]. In brief, 9795 patients with type 2 diabetes aged 50–75 years 
were randomised to 200 mg micronised fenofibrate daily (Laboratoires Fournier, Dijon, France) 
or matching placebo. All had baseline total cholesterol levels of 3.0–6.5 mmol/l, plus a total 
cholesterol:HDL-cholesterol ratio ≥4 or a triacylglycerol concentration of 1–5 mmol/l, with no 
clear indication for lipid-modifying therapy at the time of study initiation. Traditional lipid levels 
were measured on all participants at baseline, at 4, 8 and 12 months, 2 years and at the end of the 
study. Apolipoproteins A-I and B were measured at baseline, 4 months, 2 years and study close. 
Additional cardiovascular medicines, including statins and other lipid-modifying treatments, 
could be commenced during the trial at the discretion of the patient’s treating doctor. Medication 
adherence was assessed by returned tablet counts at each visit. 
All patients gave written informed consent. The FIELD protocol was approved by local 
and national ethics committees and undertaken in accordance with the Declaration of Helsinki 
and Good Clinical Practice guidelines. 
The primary endpoint, which was not statistically significant,[4] was the first occurrence 
of non-fatal MI or death from CHD. Secondary endpoints included major CVD events (the 
primary endpoint plus stroke and other CVD death). The pre-specified outcome for all subgroup 
analyses, including by sex, was total CVD events (the composite of major CVD events plus 
coronary and carotid revascularisation). Cause-specific and total mortality were also examined 
[4]. In the current detailed analysis, we explore the effects of fenofibrate by sex on total CVD and 
the component endpoints of the total CVD outcome and also the influence of sex on the effect of 
fenofibrate on lipid levels measured at baseline, 4 months, 1 year, 2 years and study close. The 
influences of menopausal status, oestrogen use, concurrent use of statins, and metformin and 
insulin therapy were assessed. All lipid analyses were performed in two central laboratories with 
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standard techniques. Rigorous quality-assurance procedures were used to verify stable assay 
characteristics, as previously reported [4]. Non-HDL cholesterol was calculated as (total 
cholesterol  HDL-cholesterol). The LDL-cholesterol level was calculated using standard 
methods [12]. Dyslipidaemia was defined a priori as fasting triacylglycerol levels ≥1.7 mmol/l in 
both sexes, and HDL-cholesterol levels <1.03 mmol/l for men and <1.29 mmol/l for women 
(according to Adult Treatment Panel [ATP] III guidelines [13]). Marked dyslipidaemia used a 
higher cutpoint of triacylglycerol levels >2.3 mmol/l, with the same sex-specific HDL-cholesterol 
cutpoints. For the purposes of this analysis, the ACCORD definition of dyslipidaemia based on 
the upper triacylglycerol and lower HDL-cholesterol tertiles, respectively (triacylglycerol >2.3 
mmol/l and HDL-cholesterol ≤0.88 mmol/l, for both women and men) was also applied. 
Apolipoprotein A-I and apolipoprotein B were measured with a nephelometer (Array Protein 
System, Beckman-Coulter, Sydney, NSW, Australia) (Australian and New Zealand samples) or a 
Cobas Mira analyser (Hoffman La Roche, Basel, Switzerland) (Finland samples). The two 
laboratories were aligned by participation in an external quality-assurance programme 
coordinated by the Canadian Reference Laboratory (Vancouver, BC, Canada) using Centers for 
Disease Control (CDC)-traceable standard materials. Day-to-day CVs were <5% throughout the 
study. 
Statistical analysis All analyses were done at the National Health and Medical Research Council 
Clinical Trials Centre (NHMRC CTC), University of Sydney. The data were analysed on an 
intention-to-treat basis with SAS (version 9.2; SAS, Cary, NC, USA). The analysis of differences 
for baseline characteristics used χ2 tests for binary variables and t tests for continuous outcomes 
unless the distribution of the data was not normal, in which case the Wilcoxon rank-sum test was 
used. Spearman correlations were computed on non-transformed data. Time-to-event analyses 
used the logrank test and the Kaplan–Meier method. HRs and 95% CIs were generated from Cox 
proportional-hazards models [13]. Analyses were adjusted for covariates (including ethnicity, 
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age, diabetes duration, BMI, waist–hip ratio, systolic and diastolic blood pressure, smoking, prior 
CVD, prior coronary revascularisation, hypertension, microvascular disease, baseline total 
cholesterol, LDL-cholesterol, HDL-cholesterol, creatinine, homocysteine, dyslipidaemia, 
microalbuminuria, macroalbuminuria, use of metformin, and use of sulfonylurea) and on-trial 
statin uptake [11]. ANOVA methods were used to assess the treatment-effect difference in the 
change in lipid and apolipoprotein levels. Heterogeneity across the sexes was assessed by 
determining the interaction term for sex between the treatment group and outcome, with 
significance drawn at two-sided p<0.05 with no adjustment for multiple comparisons. 
Results 
Baseline characteristics Women comprised 37.3% of the cohort. At the final visit, 95.0% of the 
women and 92.0% of the men allocated to placebo and 94.3% of the women and 91.3% of the 
men allocated to fenofibrate remained alive. There was no difference between women and men or 
between the two treatment groups in the rates of loss to follow-up (0.3% in all groups). 
Women were more likely to be younger, hypertensive and obese compared with men 
(Table 1). They were less likely to be current or former smokers or to have a history of prior 
CVD, and had lower plasma creatinine and homocysteine levels and lower albuminuria rates. 
Women had higher levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL 
cholesterol. They were also more likely to be dyslipidaemic and had significantly higher baseline 
apolipoprotein A-I and B levels. Use of calcium antagonists, diuretics, angiotensin II receptor 
antagonists, and metformin (alone or in combination with other glucose-control agents) was more 
common in women, whereas the use of anti-thrombotic agents (including aspirin) or 
sulfonylureas alone was less common. 
Adherence to assigned treatment and lipid drug drop-in rates At the end of the study, women and 
men had discontinued fenofibrate treatment at similar rates (19.8% vs 19.3%), equivalent to the 
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placebo discontinuation rates. There were no statistically significant differences in adherence 
rates between the sexes on the basis of returned tablet counts (data not shown). 
Among the participants allocated to fenofibrate, women were less likely than men to 
commence other active cholesterol-lowering medication, mainly statins (16.3% vs 21%, 
p<0.001), but women and men allocated to placebo had similar commencement rates of such 
medications (37.2% vs 35.7% at study close, p=0.3). 
Effect of fenofibrate therapy on lipid and apolipoprotein levels by sex Fenofibrate significantly 
reduced total cholesterol, LDL-cholesterol and triacylglycerol levels in both sexes (p<0.001) 
(Fig. 1, electronic supplementary material [ESM] Table 1). Relative to placebo, the reductions in 
total cholesterol and LDL-cholesterol with fenofibrate allocation were greater in women (all 
p<0.001): for total cholesterol, 14.0% (0.84 mmol/l) for women vs 9.9% (0.49 mmol/l) for men at 
4 months, and 9.5% (0.48 mmol/l) vs 5.2% (0.25 mmol/l) at study close; and for LDL-
cholesterol, 16.5% (0.53 mmol/l) vs 9.4% (0.31 mmol/l) at 4 months and 9.8% (0.29 mmol/l) vs 
3.3% (0.10 mmol/l) at study close. LDL-cholesterol differences entirely accounted for the 
differences in cholesterol change (Fig. 1b). Fenofibrate allocation was associated with an HDL-
cholesterol rise at 4 months relative to placebo in both sexes (5.7% [0.07 mmol/l] in women and 
4.8% [0.05 mmol/l] in men), with the difference compared with placebo diminishing over time 
(Fig. 1c). Apart from an 11% greater reduction in triacylglycerol levels at 4 months in women 
(women 30.5% reduction [0.6 mmol/l], men 27.4% reduction [–0.5 mmol/l], p=0.01), the effect 
on triacylglycerol levels was similar in men and women over 5 years (Fig. 1d). 
  At study close, fenofibrate had almost halved the percentage of patients with 
dyslipidaemia, from 42.7% to 23.9% in women (p<0.001) and from 34.0% to 20.2% in men 
(p<0.001), a significantly greater reduction in women (p=0.04). 
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Effect of statin therapy on fenofibrate-induced lipid changes The differences between treatment 
groups in total cholesterol and LDL-cholesterol in both sexes attenuated over time (ESM Fig. 1a, 
b)[4], but among patients not commencing statins, the effect of fenofibrate was preserved. The 
LDL-cholesterol-lowering effect of fenofibrate was greater in these women than men at all time 
points: 18.1% vs 10.8% at 4 months and 20.1% vs 11.2% at study close (all p<0.001) (ESM Fig. 
1). Neither statin commencement rates nor differences in body weight explained the greater LDL-
cholesterol reduction in women. 
Effect of insulin, metformin, and oestrogen therapy on fenofibrate-induced lipid changes There 
were no significant effects of initiation of metformin or insulin treatment during follow-up on the 
fenofibrate-induced lipid changes over 5 years. Only small numbers of women used oestrogen 
throughout the study, with no significant effect on lipid changes due to fenofibrate (not shown). 
Effect of fenofibrate on CVD events in women The primary endpoint of the FIELD study, non-
fatal MI plus death from CHD, was not significantly reduced by fenofibrate treatment (HR 0.89; 
95% CI 0.75, 1.05, p=0.16) [4]. Fenofibrate significantly reduced total CVD events, the pre-
specified endpoint for all subgroup analyses, overall by 11% [4]. Total CVD events were reduced 
by 20% in women and non-significantly by 8% in men, but these sex-specific treatment effects 
were not significantly different (Fig. 2). In women, allocation to fenofibrate compared with 
placebo was associated with lower rates of non-fatal MI and revascularisation procedures, but 
neither was statistically significant, whereas the 22% reduction in non-fatal MI and the 18% 
reduction in revascularisation in men allocated to fenofibrate compared with placebo were 
statistically significant. The relative benefits of fenofibrate allocation in women compared with 
men did not differ statistically for any of the CVD outcomes separately or in aggregate (all p 
values for heterogeneity >0.1) (Fig. 3). 
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Among patients who did not have CVD at study entry, fenofibrate reduced the risk of 
total CVD events by 26% (p=0.04) in women and 16% (p=0.04) in men (interaction by sex, 
p=0.45). Non-fatal MI was reduced by 41% in women (p=0.05) and 29% in men (p=0.04; 
interaction p=0.54). Fenofibrate reduced the risk of coronary events (CHD death or non-fatal MI, 
the primary study endpoint) by 41% (p=0.02) in women and 17% in men (p=0.17) and 
revascularisation by 31% in women (p=0.06) and 27% (p=0.002) in men. Again, interactions 
between sex and treatment were not statistically significant, as was also the case among those 
patients with dyslipidaemia (all interaction p values>0.24). For example, the effects of fenofibrate 
on total CVD events among those with dyslipidaemia were 24% (4% to 45%) reduction in 
women and 10% (9% to 26%) reduction in men, and among those with marked dyslipidaemia 
24% (2% to 42%) reduction in men and 30% (7% to 54%) in women [14]. Applying the 
ACCORD Lipid definition of dyslipidaemia [8] gave similar results (ESM Table 2). 
Adjusted effects of fenofibrate treatment With adjustment for statin use and other baseline 
covariates,[11] allocation to fenofibrate reduced total CVD events by 17% overall (95% CI 6%, 
17%, and in women by 30% (95% CI 8% to 46%) although not significantly in men (13%; 95% 
CI –1%, 24%), with no statistical evidence of heterogeneity of effect by sex (p=0.14). There was 
no significant reduction in non-fatal MI among women (35%; 95% CI –5%, 61%) but there was 
for men (28%; 95% CI, 5%, 47%). Revascularisation procedures were reduced by 34% (95 % CI 
7%, 55%) in women and by 27% (95% CI 13%, 40%) for men (Fig. 3). 
Safety of fenofibrate in women There were no significant differences in total cancer incidence 
with allocation to fenofibrate in either sex (ESM Table 3). Nor was there any excess of 
rhabdomyolysis, irrespective of statin commencement during follow-up in either sex. Small 
excesses of pancreatitis and pulmonary embolism with fenofibrate did not differ significantly by 
sex. End-stage renal disease requiring dialysis was not increased with treatment in men or 
women. 
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Discussion 
On the basis of ACCORD Lipid study results [8], the Food and Drug Administration reviewed 
the cardiovascular safety of fenofibrate in women with diabetes [9]. Our results indicate that 
fenofibrate is generally safe for women with type 2 diabetes. Although in the FIELD study, the 
primary endpoint of non-fatal MI plus coronary death was not significantly reduced, the 
secondary endpoint of total CVD events was reduced (without adjustment for multiple 
comparisons). Women allocated fenofibrate, including those with dyslipidaemia at baseline, had 
risk reductions in CVD events that did not differ statistically significantly from those in men, and 
for some event types tended to have greater benefit. Women also had significantly greater 
improvements in traditional lipids variables and in apolipoprotein B levels. 
Differences between treatment groups in LDL-cholesterol concentrations always 
remained larger in women, and were most clearly evident in statin-naive patients. These 
differences were not explained by differences in baseline characteristics such as body habitus, 
insulin or metformin therapy, menopausal status or oestrogen use. The apparent attenuation over 
time of the effect of fenofibrate on lipid and apolipoprotein levels in both sexes combined was 
driven by the higher rate of statin initiation in the placebo groups than in those allocated to 
fenofibrate. 
The significant differences between women and men in the effects of fenofibrate on lipid 
and apolipoproteins were unexpected. Women were lighter than men, with a smaller body surface 
area, but had a higher body mass index (BMI, 31.5 vs 29.1 kg/m2) (Table 1). Sex differences in 
mass, BMI and body surface area might be associated with differences in the volume of 
distribution or other pharmacodynamic properties of fenofibrate. Oestrogenic hormones are 
potential confounding factors, given that they are known to increase HDL-cholesterol and reduce 
LDL-cholesterol [15,16] and to influence lipoprotein-related enzyme levels. In our study, most 
women (94%) were postmenopausal (average age at study entry 61 years), but the effects of 
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fenofibrate in premenopausal and postmenopausal women were not different for lipoprotein 
measures or for clinical CVD event reductions, and too few women continued exogenous 
oestrogen therapy to have any plausible impact on the results. Nor did insulin use or differences 
in statin uptake between the sexes explain the difference in LDL-cholesterol and fenofibrate 
response (see ESM Fig. 1 and Simes et al [11]). Uptake of statin therapy during the trial may have 
confounded the treatment effects. We adjusted the results for statin uptake (and covariates), 
which is considered a better method of accounting for this than using analytical methods that do 
not maintain the randomised comparisons [11]. In fact, there was little difference between the 
unadjusted results and the results adjusted for statin use and covariates. Metformin use, which can 
improve the lipid profile [17], was more common in women, but in FIELD, metformin use did 
not contribute materially to the observed sex differences in lipid and apolipoprotein changes. 
Previous studies with fenofibrate or, indeed, any fibrate have not reported a sex 
difference in responsiveness to therapy. However, most of the large prospective CVD 
intervention studies with fibrate monotherapy have either not included women or have had 
relatively small numbers of women [5, 6], and even fewer have had women with diabetes. 
The ACCORD Lipid study had 1694 women (31% of patients) randomly assigned to 
fenofibrate or placebo on background statin therapy [8]. Lipid changes by sex in ACCORD Lipid 
have yet to be published in a journal article, but have been reported to the US Food and Drug 
Administration [9] and show larger LDL-cholesterol reductions in women. In contrast to our 
study, ACCORD Lipid reported that  the primary outcome (CVD death or non-fatal MI or non-
fatal stroke) was less frequent (11.2%) in men using the combination of fenofibrate and 
simvastatin than in men receiving simvastatin alone (13.3%), but the rate for women was non-
significantly more frequent in the combination therapy group (9.1% vs 6.6%); the difference 
between the sexes was significant (p=0.01 for interaction). Such sex-specific differences in 
treatment benefits were not apparent among participants with dyslipidaemia in ACCORD Lipid 
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[18], where CVD benefits were greatest [8]. FIELD has also reported similarly large CVD 
benefits in men and women with diabetes and dyslipidaemia [19]. Only a small number of women 
in FIELD met the ACCORD Lipid definition for dyslipidaemia, but patterns of fenofibrate effect 
among them were similar to those for men (ESM Table 2). 
There are several potential reasons for the discrepant results between FIELD and 
ACCORD Lipid. All patients in ACCORD Lipid but fewer than one-third of FIELD patients 
received statin therapy. Patients in FIELD may have had a higher background risk by virtue of 
not being on statin therapy at randomisation, but they had a shorter duration of diabetes and a 
lower HbA1c at study entry. Nevertheless, CVD event rates among women in the control arm in 
FIELD appeared to be about 50% higher than in ACCORD Lipid (ESM Table 2). The apparent 
higher event rate combined with the greater number would offer substantially more power in 
FIELD to evaluate the effects of fenofibrate in women. It is possible that the non-significantly 
adverse CVD result for women in ACCORD Lipid was just the play of chance. It is important to 
note that event rates were reduced similarly in dislipidaemic women and men in ACCORD Lipid 
[19]. The results do suggest that the combination of fenofibrate with a statin will be most 
beneficial for CVD prevention in patients with dyslipidaemia on statin therapy and are consistent 
with findings in FIELD that the effect is greatest in patients with dyslipidaemia [19]. 
Conclusion 
In summary, the FIELD study showed that both men and women with diabetes had significantly 
improved lipoproteins  with fenofibrate therapy, with changes in women being greater than in 
men. The primary endpoint of the study was not statistically significantly reduced, but total CVD 
events were significantly lowered with allocation to fenofibrate. In pre-specified analyses by sex, 
there was no evidence that women did worse than men and for several endpoints, including total 
CVD events, there was a trend suggesting that women may have benefited more. These benefits 
were particularly large in those with dyslipidaemia, consistent with the findings in ACCORD 
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Lipid. These results suggest that fenofibrate is effective for improving an adverse lipoprotein 
profile and for reducing total CVD event risk in women with type 2 diabetes, especially those 
with dyslipidaemia. 
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 Table 1 Baseline characteristics and medication 
Characteristic 
Women 
(n=3657) 
Men 
(n=6138) 
Age at visit 1, years 61.8 (6.9) 62.5 (6.9)*** 
Diabetes duration, years 5 (2–9) 5 (2–10)*** 
Weight, kg 81.7 (71.3–94) 88.7 (80–99.3)*** 
BMI, kg/m2 31.5 (27.8–36) 29.1 (26.4–32.2)*** 
Body surface area, m2 a 2.1 (0.2) 2.3 (0.2)*** 
Risk factors   
  Waist-to-hip ratio 0.87 (0.83–0.92) 0.96 (0.93–1)*** 
  HbA1c, % 6.9 (6.1–7.8) 6.9 (6.1–7.8) 
  HbA1c, mmol/l 8.4 (7.1–9.8) 8.4 (7.1–9.8) 
  Plasma creatinine, µmol/l 67.6 (13.4) 83.4 (13.9)*** 
  Homocysteine, µmol/l 8.9 (7.5–10.9) 9.9 (8.3–11.8)*** 
  Microalbuminuria, % b 17.23 24.10*** 
  Macroalbuminuria, % b 2.8 4.9*** 
  Blood pressure, mmHg 141/81 140/83 
  Prior CVD, % 18.7 23.6*** 
  History of hypertension, % 63.7 52.4*** 
  Prior microvascular disease, % 18.0 22.3*** 
  Current or ex-smoker 41.6 70.8*** 
Lipid and apolipoprotein variables   
  Total cholesterol, mmol/l 5.21 (0.7) 4.93 (0.69)*** 
  LDL-cholesterol, mmol/l 3.12 (0.67) 3.03 (0.64)*** 
  HDL-cholesterol, mmol/l 1.21 (0.28) 1.03 (0.23)*** 
  Non-HDL cholesterol, mmol/l 4.01 (0.70) 3.90 (0.67)*** 
  Triacylglycerol, mmol/l 1.79 (1.4–2.3) 1.70 (1.3–2.3) 
  Dyslipidaemia, % 43.1 34.8*** 
  Apolipoprotein A-I, g/l 1.32 (1.19-1.47) 1.18 (1.07-1.30)*** 
  Apolipoprotein B, g/l 0.99 (0.18) 0.96 (0.17)*** 
Cardiovascular medication, %   
  Anti-thrombotic agents 27.2 33.8*** 
  ACE inhibitors or angiotensin II receptor 
antagonist 
41.0 37.3*** 
  β blocker 15.4 14.0 
  Calcium antagonist 21.2 18.2*** 
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Characteristic 
Women 
(n=3657) 
Men 
(n=6138) 
  Nitrate 5.5 5.7 
  Diuretic agent 22.3 10.9*** 
Blood-glucose-lowering medication, %   
  Metformin alone 20.6 15.8*** 
  Any metforminc 51.9 47.2*** 
  Sulfonylurea alone 13.7 18.1*** 
  Sulfonylurea and metformin 22.9 24.1 
   
  Insulin alone or with oral agent 13.7 13.8 
Data are mean (SD) for discrete variables, median (interquartile range) for continuous variables, or % 
aBased on the DuBois–DuBois formula 
bMicroalbuminuria: urine albumin/creatinine ratio 2.5–25 mg/mmol for women and 3.5–35 mg/mmol for men; 
and macroalbuminuria: urine albumin/creatinine ratio >25 mg/mmol for women and >35 mg/mmol for men 
c Alone or with any other glucose-control agent 
***p<0.001 for difference between women and men 
 
 
 
Figure legends 
Fig. 1 Absolute lipid changes with fenofibrate compared with placebo from baseline to study 
close in women and men (measured at clinic visits at 4 months, 1 year, 2 years and study close [5 
years]). (a) Total cholesterol; (b) LDL-cholesterol; (c) HDL-cholesterol; (d) triacylglycerols; (e) 
apolipoprotein A-I; and (f) apolipoprotein B. The reduction in non-HDL cholesterol level by 
fenofibrate relative to placebo was greater in women than men at all time points. Apolipoprotein 
A-I and HDL-cholesterol were significantly correlated at each time point (r= 0.45 to r=0.65, all 
p<0.01). Apolipoprotein B levels paralleled the patterns of non-HDL cholesterol (r=0.74 to 
r=0.91), LDL-cholesterol (r=0.63 to r=0.85) and triacylglycerol levels (r=0.25 to r=0.46) (all 
p<0.01). Red dashes, women, placebo; red solid line, women, fenofibrate; blue dashes, men, 
placebo; blue solid line, men, fenofibrate; m, months; y, years 
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Fig. 2 Cumulative cardiovascular event rates in patients assigned to fenofibrate (red lines) and 
placebo (black lines). Allocation to fenofibrate compared with placebo reduced total 
cardiovascular events (HR 0.89, 95% CI 0.80, 0.99, p=0.035). For women the HR was 0.80, 95% 
CI 0.64, 0.99, p=0.04; for men HR 0.92, 95% CI 0.81, 1.05, p=0.2; sex-by-treatment interaction 
p=0.3; p values are unadjusted for multiple comparisons. Lighter red, women, placebo; 
 darker red, women, fenofibrate; lighter blue, men, placebo; darker blue, men, fenofibrate 
Fig. 3 HRs with 95% CIs for the effect of fenofibrate compared with placebo for cardiovascular 
outcomes in 3,657 women and 6,138 men, unadjusted and adjusted for uptake of statin therapy 
and baseline covariates (ethnicity, age, diabetes duration, BMI, waist–hip ratio, systolic blood 
pressure, diastolic blood pressure, smoking, prior cardiovascular disease, prior coronary 
revascularisation, hypertension, microvascular disease, baseline total cholesterol, LDL-
cholesterol, HDL-cholesterol, creatinine, homocysteine, dyslipidaemia, microalbuminuria, 
macroalbuminuria, use of metformin and use of sulfonylurea). ap for heterogeneity between men 
and women. bCardiovascular events was the pre-specified outcome for subgroups 
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ESM table 1: Plasma concentration of lipids at baseline and study close by sex, with treatment group differences during follow-up. 
 
 
Plasma concentration at 
baseline (mean (SD)) 
Absolute (mmolL) and relative (%) differences between treatment groups in 
plasma lipid concentration after randomisation 
Plasma concentration at 
study close (mean (SD)) 
Parameter Placebo Fenofibrate 4 months 1 year 2 years Study close Placebo Fenofibrate 
Women         
Total cholesterol 5.21 (0.70) 5.22 (0.69) -0.74 (-14.0) -0.73 (-13.9) -0.72 (-13.9) -0.48 (-9.5) 4.80 (0.91) 4.33 (0.79) 
LDL cholesterol 3.12 (0.68) 3.12 (0.65) -0.53 (-16.5) -0.51 (-16) -0.51 (-16.5) -0.29 (-9.8) 2.70 (0.80) 2.40 (0.66) 
HDL cholesterol 1.21 (0.28) 1.20 (0.27) 0.07 (5.7) 0.06 (5.2) 0.04 (3.0) 0.01 (1.0) 1.23 (0.31) 1.24 (0.33) 
Triacylglycerols 1.93 (0.77) 1.99 (0.8) -0.6 (-30.5) -0.62 (-31.6) -0.55 (-28.2) -0.46 (-23.9) 1.93 (0.91) 1.52 (0.79) 
Non-HDL cholesterol 4.00 (0.71) 4.02 (0.69) -0.8 (-20.0) -0.79 (-19.8) -0.76 (-19.2) -0.49 (-12.9) 3.57 (0.90) 3.09 (0.80) 
Apolipoprotein AI 1.35 (0.22) 1.34 (0.22) 0.06 (4.8) —
a
 0.03 (2.4) 0.02 (1.9) 1.28 (0.22) 1.30 (0.23) 
Apolipoprotein B 0.99 (0.18) 0.99 (0.17) -0.17 (-17.3) —
a
 -0.15 (-15.7) -0.10 (-10.4) 0.90 (0.23) 0.81 (0.21) 
Men         
Total cholesterol 4.93 (0.70) 4.93 (0.68) -0.49 (-9.9) -0.50 (-10.2) -0.46 (-9.4) -0.25 (-5.2) 4.41 (0.85) 4.18 (0.76) 
LDL cholesterol 3.03 (0.64) 3.04 (0.63) -0.31 (-9.4) -0.30 (-9.4) -0.27 (-8.8) -0.10 (-3.3) 2.53 (0.77) 2.45 (0.65) 
HDL cholesterol 1.03 (0.22) 1.03 (0.23) 0.05 (4.8) 0.04 (4.0) 0.04 (3.7) 0.01 (1.4) 1.06 (0.26) 1.07 (0.27) 
Triacylglycerols 1.93 (0.95) 1.93 (0.91) -0.54 (-27.4) -0.56 (-29.3) -0.51 (-27.0) -0.38 (-20.7) 1.83 (0.98) 1.44 (0.77) 
Non HDL cholesterol 3.90 (0.68) 3.90 (0.66) -0.54 (-13.8) -0.54 (-14.1) -0.49 (-13.1) -0.26 (-7.2) 3.35 (0.83) 3.1 (0.77) 
Apolipoprotein AI 1.20 (0.18) 1.20 (0.19) 0.04 (3.4) —
a
 0.03 (2.6) 0.02 (1.8) 1.15 (0.20) 1.17 (0.20) 
Apolipoprotein B 0.96 (0.17) 0.96 (0.17) -0.11 (-11.4) —
a
 -0.09 (-10.1) -0.05 (-5.8) 0.86 (0.23) 0.82 (0.21) 
a
 Not measured 
HDL, high-density lipoprotein; LDL, low-density lipoprotein 
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***
***** * * *
Relative differences in lipid changes from baseline to study close between placebo and fenofibrate 
groups, for women and men in subgroups of statin use or no statin use (measured at clinic visits at 4 months, 
1 year, 2 years, and study close). Dotted lines show persistence of differences over time among patients 
who did not use statin therapy. Solid lines show randomised groups, in which differences were attenuated 
due to uptake of statin therapy, particularly in the placebo group. *p<0.001 for differences between women 
and men, for the full cohort and for those not using statins.
Favourable effects of fenofibrate on lipids and cardiovascular disease in 
women with type 2 diabetes: results from the Fenofibrate Intervention and 
Event Lowering in Diabetes (FIELD) study
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The authors wish to point out two typographical errors in Fig. 3. In the fenofibrate arm, the proportion 
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